Azilect rasagiline: Phase IV data

Data from a double-blind, placebo-controlled Phase IV trial in 179 healthy volunteers showed that 1 mg Azilect resulted in tyramine sensitivity comparable to fellow MAO-B inhibitor selegiline and "sub...